Palvella Therapeutics
PVLA----
Palvella Therapeutics (PVLA)
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Palvella Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 27, 2026Price forecast
$229.6057.27%
Forecast & RatingStrong buy
15analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- rttnews · Jul 21 at 10:25 PM
Top Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing
- Tip Ranks · Jul 21 at 03:19 PM
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
- Tip Ranks · Jul 21 at 11:26 AM
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst
- PUBT · Jul 17 at 03:06 PM
Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57
- TradingView · Jul 14 at 03:54 PM
Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash
- PUBT · Jul 1 at 03:06 PM
Palvella Therapeutics director Matthew Pauls files initial beneficial ownership statement
